Navigation Links
SCOLR Pharma Announces Unaudited Net Sales of Nutritional Products
Date:6/20/2012

BOTHELL, Wash., June 20, 2012 /PRNewswire/ -- SCOLR Pharma, Inc. (PINK: SCLR) today reported unaudited net sales of its nutritional products for the fourth quarter and year ended December 31, 2011 and the first quarter ended March 31, 2012. 

Unaudited net sales of nutritional products were $252,000 for both the fourth quarter and year ended December 31, 2011.  Unaudited net sales of nutritional products were $454,000 for the first quarter ended March 31, 2012. 

SCOLR announced the first shipments of its nutritional products in December 2011 and did not record net sales of nutritional products for the first three quarters of 2011.  SCOLR's products, which are based on the Company's proprietary CDT® Controlled Delivery Technology platform, are sold directly to retailers in the mass consumer products channel and are available to consumers under private label and the SCOLR® CDT® brand-name.  

Stephen Turner, President and CEO of SCOLR, said: "We are gratified to see our direct sales and marketing efforts begin to generate revenues and repeat sales.  We are working with retailers to expand the number and type of products available to consumers and we hope to continue the current momentum into the remainder of this launch year.  The proceeds of our recently closed financing will be used primarily to fund inventory and promotional needs in support of these efforts. We will continue to focus on our short term goal of profitably growing and stabilizing our nutritional business, while preparing for the eventual commercialization of our ibuprofen product."

SCOLR recently announced the closing of a private placement financing in which it raised gross proceeds of $1.35 million through the sale of its 8% Secured Convertible Debentures due June 2013. 

About SCOLR Pharma:

Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT® platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Its CDT® drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call (425) 368-1050 or visit http://www.scolr.com/.

Forward looking statements:                                              

Any statements made in this press release that relate to future plans, events or performance are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward looking statements include statements regarding the use of proceeds of a financing transaction, efforts to expand the number and type of nutritional products available to consumers, future profitability, and potential commercialization of SCOLR's Ibuprofen product.  Factors that could cause these forward-looking statements to differ from actual results include adverse consumer or retailer reception of SCOLR's products, SCOLR's inability to source adequate inventory of its products in a timely matter and on favorable terms, any adjustments to the preliminary unaudited results presented herein, unfavorable regulatory determinations, competitive factors and other risks and uncertainties discussed in the company's periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission.  SCOLR Pharma, Inc. undertakes no obligation to update or revise any forward-looking statements.

Contacts:
Investor Relations:                                             
SCOLR Pharma, Inc.                                            
425.368.1050

 


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SCOLR Pharma Welcomes Clem Calabrese as Director of Field Sales
2. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
3. CPhI South America 2012 Returns to Brazil with One of a Kind Pharma Event
4. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
5. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
6. Sentry BioPharma Services Invests in Global Clinical Supply Services with -45C Freezer Expansion
7. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
8. Oregon State University Launches New Online Learning System For Pharmacy Managers
9. Tris Pharma to Hold Job Fairs - Saturday, June 16 and Saturday, June 23
10. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
11. NABP Applies for New .PHARMACY Generic Top-Level Domain to Provide a Secure Destination for Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Venture ... Golf Classic Tournament held on June 20th at the Woodmont Country Club at ... Luke’s Wings, an organization dedicated to helping service members that have been wounded in ...
Breaking Medicine News(10 mins):